1. David W. Kolstad

    0 Comments Leave a Comment

    1-17 of 17
    1. Mentioned In 17 Articles

    2. LightLab Imaging Announces FDA Clearance of C7-XR™ Coronary OCT Products in the United States

      LightLab Imaging Announces FDA Clearance of C7-XR™ Coronary OCT Products in the United States
      ...f-the art intracoronary OCT systems to leading hospitals outside of the United States for over 5 years,” said David Kolstad, CEO of LightLab Imaging. “With our clearance by the FDA, U.S. clinicians now have access to a f...
      Read Full Article
    3. 1st Massachusetts General Hospital OCT Registry Symposium Scheduled for March 13, 2010

      1st Massachusetts General Hospital OCT Registry Symposium Scheduled for March 13, 2010
      The utilization of OCT has grown tremendously since the launch of the world’s first frequency domain OCT system (FD-OCT) from LightLab Imaging, Inc. in late 2009. Over 9,000 cases were performed last year, slightly less than the cumulative cases performed in the three years prior with the older Time Domain OCT which was much slower and harder to use. “OCT has come a long way". States Dr. Ik-Kyung ...
      Read Full Article
    4. Lightlab Imaging Leads Global Advancement of Intracoronary Imaging

      ...OCT.   “From all perspectives, LightLab is recognized as the clear global leader in intravascular OCT,” said David Kolstad, LightLab Imaging’s President and CEO.  “During 2008, we continued to execute strategies that wi...
      Read Full Article
    5. Intravascular Optical Coherence Tomography Opens a Window onto Coronary Artery Disease

      Intravascular Optical Coherence Tomography Opens a Window onto Coronary Artery Disease
      In the United States alone, more than 650,000 people die each year of heart attacks related to coronary artery disease. A new technique, intravascular optical coherence tomography, may play an important role in guiding therapeutic interventions, diagnosing atherosclerosis and researching the causes of coronary artery disease.
      Read Full Article
    6. 1-17 of 17
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About David W. Kolstad

    David W. Kolstad is President and CEO of Lightlab Imaging. Mr. Kolstad brings over 18 years of imaging and cardiac medical device experience to the business. He has provided senior management leadership for corporate strategy, marketing, business development, product and general management to large and small businesses. His experience includes senior management positions with Fortune 500 companies, Hewlett-Packard and General Electric, as well as venture and corporate backed start-ups. Mr. Kolstad received his MBA from The Amos Tuck School of Business Administration at Dartmouth and his BS in Chemical Engineering from the Worcester Polytechnic Institute. Mr. Kolstad rejoins LightLab imaging where he previously served as Vice President of Sales, Marketing and Business Development from 1999 – 2004. Mr. Kolstad previously served in executive roles with Viacor Inc, Transmedics Inc., and as Vice President of Worldwide Marketing and interim General Manager for Hewlett-Packard’s global medical imaging business. He began his career as a member of General Electric’s management development program and served as a surf rescue boat coxswain in the US Coast Guard reserves.

  3. Quotes

    1. The LightLab team is excited to join St. Jude Medical, and we look forward to further strengthening the company's interventional cardiology business with the OCT technology. There is a strong alignment between St. Jude Medical and LightLab both in our product portfolios and our shared vision of improving patient outcomes through solutions which enable physicians to make earlier and more accurate treatment decisions.
      In St. Jude Medical Completes Acquisition of LightLab Imaging
    2. The global market for optical coherence tomography will reach $1.3 billion within five years.
      In New system sharpens the view inside blood vessels
    3. One year after the launch of our C7-XR system at PCR, the results throughout Europe have been outstanding...This has been a tremendous year for LightLab OCT both in Europe and in the United States, with the achievement of our FDA clearance and US introduction earlier this month. We are pleased with our progress toward LightLab OCT becoming the worldwide intracoronary imaging gold-standard.
      In LightLab Imaging Returns to EuroPCR 2010 With Strong and Growing Worldwide Acceptance of C7-XR OCT Imaging System
    4. We are excited to join with a partner who shares our vision of improving patient outcomes and reducing health care costs through solutions which enable physicians to make earlier and more accurate treatment decisions... We believe St. Jude Medical's U.S. and international footprint, along with its existing FFR measurement technology, will accelerate growth for our industry-leading OCT technology. We look forward to joining the St. Jude Medical team.
      In St. Jude Medical to Acquire LightLab Imaging for $90M in Cash
    5. LightLab has been delivering state-of-the art intracoronary OCT systems to leading hospitals outside of the United States for over 5 years...With our clearance by the FDA, U.S. clinicians now have access to a fast and easy-to-use, high-resolution imaging system. We believe C7-XR Imaging System and C7 Dragonfly Imaging Catheter will enhance the diagnostic information and procedural control available to U.S clinicians. We will begin offering the C7-XR Imaging System and the C7 Dragonfly Imaging Catheter immediately.
      In LightLab Imaging Announces FDA Clearance of C7-XR™ Coronary OCT Products in the United States
    6. SCAI is an important show for LightLab and a great opportunity for us to demonstrate the clinical advantages of our products...The C7-XR system has provided clinicians in Europe a significant advancement in imaging speed and clinical data available to them during therapeutic procedures..
      In LightLab Highlights OCT Market Leadership at the Society for Cardiovascular Angiography and Interventions
    7. We are pleased and honored to receive the Prism Award for our C7 XR Imaging System, as this represents an important recognition of this product from a Society representing the top innovators in optics and photonics.
      In LightLab Imaging Receives Prism Award
    8. We are very pleased to bring our most advanced platform, the C7-XR system to GE and LightLab's joint customers. We believe that improving cath lab workflow, as well as the capabilities of these highly complementary imaging technologies, will benefit clinicians, patients and payors alike.
      In GE Healthcare and LightLab Imaging Inc. Collaborate on Cardiovascular Imaging
    9. During 2008, we continued to execute strategies that will further extend our leadership position in the year ahead.
      In LightLab's cardiac OCT progress sets stage for new developments
    10. From all perspectives, LightLab is recognized as the clear global leader in intravascular OCT.
      In Lightlab Imaging Leads Global Advancement of Intracoronary Imaging